BLOOD REVIEWS血液评论
BLOOD REVIEWS(英文缩写 BLOOD REV),ISSN 0268-960X,eISSN 1532-1681,中文译名:血液评论 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 10.636 | Q1 |
| 2022 | 7.400 | Q1 |
| 2023 | 6.900 | Q1 |
| 2024 | 5.700 | Q1 |
| 2025 | 7.200 | Q1 |
BLOOD REVIEWS 最新收录文献
-
1. Neonatal antiphospholipid syndrome-associated thrombosis: Diagnostic pitfalls and therapeutic frontiers.
1. 新生儿抗磷脂综合征相关血栓形成：诊断陷阱与治疗前沿PMID:日期:2026-09-11Neonatal antiphospholipid syndrome (APS) is an exceptionally rare but clinically significant thrombotic disorder associated with antiphospholipid antibodies (aPL) in the neonatal period. Two principal pathogenic mechanisms have been proposed: passive transplacental transfer of maternal antiphospholipid antibodies and de novo neonatal production of aPL. Although approximately 30% of neonates born to aPL-positive mothers exhibit detectable antibodies at birth, thrombotic complications remain exceedingly uncommon. A "second-hit" model involving additional prothrombotic triggers such as infection, perinatal stress, inherited thrombophilia, or vascular catheters likely contributes to thrombogenesis. Available evidence from case reports and small series indicates that arterial thrombosis predominates, particularly neonatal arterial ischemic stroke, while venous thrombosis is less frequent. Diagnosis remains challenging because no validated neonatal-specific classification criteria exist, and interpretation of laboratory findings is confounded by transient maternal antibody transfer. Current diagnostic approaches rely on clinical suspicion, thrombosis confirmation, maternal antibody testing, serial neonatal aPL measurements, and exclusion of other prothrombotic conditions. Management strategies are extrapolated from pediatric and adult APS guidelines, with low-molecular-weight heparin representing the mainstay of anticoagulant therapy in affected neonates. Neonatal APS remains a diagnostic challenge due to its rarity and atypical presentations. Establishing age-specific criteria and long-term neurodevelopmental follow-up is critical for improving clinical outcomes and understanding the prognosis of this early-onset autoimmune condition. This narrative review aims to summarize current evidence regarding the pathophysiology, clinical manifestations, diagnostic challenges, and management of APS-associated thrombosis regarding the distinct neonatal population.
-
2. Beyond the platelet count: A systematic review of artificial intelligence in immune thrombocytopenia.
2. 超越血小板计数：免疫性血小板减少症中人工智能的系统综述PMID:日期:2026-09-11Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder with variable disease course, bleeding risk, and treatment response. Artificial intelligence (AI) and machine learning (ML) approaches may address diagnostic and therapeutic challenges by identifying complex patterns across heterogeneous clinical and biological data. A systematic search of PubMed, Embase, Web of Science and Scopus from inception to 13 August 2026 was conducted for studies applying ML to patient-level prediction in primary or disease-associated secondary ITP. Twelve studies were included, eleven from China, applying a range of machine learning approaches. Reported areas under the curve ranged from 0.693 to 0.937, but only two studies reported estimates from independent cohorts. Risk of bias was assessed using PROBAST+AI and eleven of the 12 studies were at high risk of bias. Further development with external validation and prospective evaluation in real-world clinical workflows is needed before these tools can be integrated into clinical practice.
-
3. Sequencing CD19-targeted therapies in patients with relapsed/refractory large B-cell lymphoma: A narrative review.
3. 复发/难治性大B细胞淋巴瘤患者中CD19靶向治疗的序贯策略：叙述性综述PMID:日期:2026-09-04CD19 is expressed on B cells from an early stage and in most B-cell malignancies, but not in hematopoietic stem cells or other normal tissues, thereby making it an attractive therapeutic target for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphomas. While CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapies, monoclonal antibodies, and antibody-drug conjugates are effective therapies for B-cell lymphomas, outcomes in the R/R setting may depend on exposure to prior treatments with the same antigen. There are limited data on the impact of sequencing these treatment modalities. This review highlights recent trial and real-world data focusing on the efficacy and safety of the CD19-targeted agents tafasitamab-lenalidomide and loncastuximab tesirine before and after CAR-T therapy in patients with R/R B-cell lymphoma and addresses the importance of assessing pretreatment target antigen levels as well as identifying common molecular mechanisms of treatment failure. Additionally, this analysis discusses the unmet needs in patients with high-risk disease and the challenges of sequencing these therapeutic strategies, while providing expert clinical practice recommendations to optimize patient outcomes.
-
4. Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data.
4. 重新审视慢性髓性白血病超越生存的结局：生活质量与以患者为中心数据的视角PMID:日期:2026-08-31The introduction and refinement of tyrosine kinase inhibitors (TKIs) over the past 25 years have resulted in dramatic improvements in life expectancy in individuals with chronic myeloid leukemia (CML). There are now multiple effective and well-tolerated TKIs available, and because most patients will be receiving TKIs for their lifetime, quality-of-life (QoL) considerations are an increasing concern. Patients with CML receiving TKIs have worse QoL than the general population, but TKIs have a generally less negative impact on QoL factors than previously available treatments for CML. Commonly used TKIs (imatinib, nilotinib, dasatinib, bosutinib, ponatinib, asciminib, and olverembatinib) all have positive and negative impacts on QoL, each of which can be impacted by patient preference and priorities, as well as line of therapy. The inclusion of patient-reported QoL outcomes in clinical trials will be vital to helping physicians understand the patient experience of CML and thereby improve disease management.
-
5. Non-transfusion-dependent β-thalassemia: A disease of clinical paradoxes.
5. 非输血依赖型β地中海贫血：一种临床悖论性疾病PMID:日期:2026-08-27Non-transfusion-dependent β-thalassemia (NTDT) was historically regarded as a relatively mild form of thalassemia because patients survive without regular transfusion therapy. However, growing evidence has challenged this perception and uncovered substantial morbidity and premature mortality driven by chronic anemia, iron overload, and hypercoagulability. This review examines three major clinical paradoxes that have reshaped the understanding of NTDT: the anemia paradox, whereby transfusion-independent patients may actually benefit from anemia correction; the iron overload paradox, characterized by clinically significant iron accumulation despite minimal or no transfusion exposure; and the hypercoagulability paradox, whereby chronic anemia coexists with a prothrombotic state. These evolving concepts have transformed NTDT from a condition traditionally managed through observation into a disease requiring proactive, risk-based intervention.
-
6. Advances in differentiation syndrome in acute promyelocytic leukemia: From mechanisms to management.
6. 急性早幼粒细胞白血病分化综合征的研究进展：从机制到管理PMID:日期:2026-08-26Differentiation syndrome (DS) is a life-threatening complication of all-trans retinoic acid and arsenic trioxide therapy for acute promyelocytic leukemia (APL). This review synthesizes the current understanding of DS pathogenesis, from PML::RARA degradation to cytokine storm, endothelial injury, and multi-organ damage, alongside diagnostic criteria, severity grading, and risk stratification. We describe a graded treatment framework encompassing prophylactic, therapeutic, and refractory-phase strategies, with particular emphasis on special populations, predictive models, and emerging therapies. Integrating mechanistic insights with risk-adapted, stepwise therapeutic strategies is essential to reduce DS-associated morbidity and mortality, thereby further improving outcomes in this highly curable disease.
-
7. Targeting the hepcidin-ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies.
7. 靶向真性红细胞增多症中的铁调素-膜铁转运蛋白轴：一种针对克隆性疗法的补充方法PMID:日期:2026-08-26Polycythemia vera (PV) is a clonal myeloproliferative neoplasm in which erythrocytosis, although driven by constitutive JAK2 signaling, remains dependent on iron availability. This dependency provides a rationale for therapeutic targeting of the hepcidin-ferroportin axis, whose modulation induces functional iron restriction and constrains erythropoiesis. The hepcidin mimetic rusfertide has shown durable hematocrit control and marked reduction of phlebotomy requirements across phase 2 and phase 3 studies, with predictable changes in systemic iron markers. However, current evidence is largely based on surrogate hematologic endpoints, and whether iron-directed strategies reduce thrombotic risk or modify disease trajectory remains undefined. Within this framework, iron metabolism can be viewed as a downstream, regulatable determinant of erythropoietic output, distinct from but integrated with clonal and inflammatory signaling. This review summarizes biological and clinical evidence on iron homeostasis in PV, focusing on the hepcidin-ferroportin axis and its integration with clone-directed therapies.
-
8. Biomarkers of joint and bone diseases, and their associations to haemophilic arthropathy in people with haemophilia: A first systematic review.
PMID:日期:2026-07-07Despite therapeutic progress, haemophilic arthropathy persists due to recurrent haemarthrosis. With joint preservation as a central objective, sensitive and standardised biomarkers are needed. To review molecular biomarkers of inflammation, joint and bone diseases in people with haemophilia (PwH) compared with healthy controls and assess associations with arthropathy. Systematic searches (PubMed, Web of Science) and PICOS-based selection of cross-sectional/case-control studies. Thirty-four studies were included; Compared with controls, PwH showed higher inflammatory activity as well as altered cartilage and bone turnover. Associations with imaging and clinical scores were present but heterogeneous, influenced by factors such as bleed timing, age, treatment exposure, comorbidities, and assay variability. Current biomarkers distinguish PwH from healthy controls but lack standardisation, specificity and validated prognostic value. Priorities include harmonisation and longitudinal validation of multi-biomarker panels integrated with imaging and patient-reported outcomes to monitor subclinical disease and guide personalised therapy.
-
9. What population-based databases reveal about equity in access to hematopoietic cell transplant and cellular therapy.
PMID:日期:2026-07-01Large population-based databases are increasingly used to study access to hematopoietic cell transplantation (HCT) and chimeric antigen receptor T-cell (CAR-T) therapy. We conducted a systematic scoping review of studies using US databases (1/2008-2/2025) to examine access to HCT or CAR-T therapy for hematologic malignancies to identify limitations and explain differences in reported disparities. Thirty-five studies met inclusion criteria, and 46% used linked databases. Across data sources, older age, racial and ethnic minoritized status, lower neighborhood socioeconomic status, and non-private insurance were associated with lower likelihood of HCT and CAR-T receipt. However, disparities varied substantially by databases due to differences in eligible populations, data availability, and ability to identify treatment candidacy. No single database adequately characterizes disparities in access to cellular therapies. Equity-focused research requires deliberate alignment of research questions with database strengths and greater investment in data standardization and inclusion of social determinants of health.
-
10. A tale of two sites - Distinct spatial differences between bone marrow and extramedullary AML.
10. 双位点的故事——骨髓与髓外急性髓系白血病之间显著的空间差异PMID:日期:2026-07-01Acute myeloid leukemia (AML) is the most common acute leukemia in adults and remains associated with poor overall survival. Beyond genetic factors in the bone marrow (BM) that drive clonal evolution, leukemic progression, immune evasion, and therapy resistance, far less is known about extramedullary (EM) AML, a clinically relevant manifestation characterized by leukemic infiltration of peripheral tissues and frequently associated with adverse outcomes. This review focuses on the spatial heterogeneity of AML, differentiating between BM and EM disease, elucidating how niche components shape leukemic behavior, clonal evolution, and treatment resistance. Furthermore, we review current clinical practice and evidence for the clinical approach, diagnostic management, and treatment of patients with EM AML. At last, we highlight the transformative role of spatial analysis platforms, enabling high-resolution mapping of niche cell and leukemic cell interactions and discuss their potential to improve diagnosis and personalized therapeutic strategies for EM AML.